Sie Djohan - PT Kalbe Management Devel
| PTKFF Stock | USD 0.1 0.01 13.55% |
Executive
Mr. Sie Djohan serves as Director of PT Kalbe Farma Tbk since June 5, 2017. He obtained a degree in Pharmacy from Universitas Indonesia in 1990. He started his career in Kalbe Group acting as Group Marketing Manager of PT Dankos Farma in 19962001, then acted as Assistant Director of Marketing of PT Dankos Farma in 20012006. In 20062007 he acted as Assistant Director of Business Development Management System, PT Kalbe Farma Tbk, and in year 2007 present he acts as Director of Business Development, Management System Regulatory Affairs of PT Kalbe Farma Tbk. since 2017.
| Age | 56 |
| Tenure | 7 years |
| Phone | 62 21 4287 3888 |
| Web | https://www.kalbe.co.id |
PT Kalbe Management Efficiency
The company has return on total asset (ROA) of 0.106 % which means that it generated a profit of $0.106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1673 %, meaning that it generated $0.1673 on every $100 dollars invested by stockholders. PT Kalbe's management efficiency ratios could be used to measure how well PT Kalbe manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sumant Rajendran | Scilex Holding | N/A | |
| Cristina Wilbur | Roche Holding AG | 56 | |
| Alan Russell | Amgen Inc | N/A | |
| Shannon Klinger | Novartis AG ADR | 49 | |
| Johanna Mercier | Gilead Sciences | 54 | |
| Etienne Jousseaume | Novartis AG ADR | N/A | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Steffen Lang | Novartis AG | 56 | |
| Ian Thompson | Amgen Inc | N/A | |
| Flavius MD | Gilead Sciences | N/A | |
| Gigi DeGuzman | Scilex Holding | N/A | |
| Elaine Chan | Scilex Holding | N/A | |
| Linda Higgins | Gilead Sciences | 62 | |
| Vasant Narasimhan | Novartis AG ADR | 48 | |
| Justin Claeys | Amgen Inc | N/A | |
| Elaine Chan | Scilex Holding | N/A | |
| Jeffrey JD | AstraZeneca PLC ADR | N/A | |
| Aharon Gal | Novartis AG ADR | N/A | |
| Samit MD | Bristol Myers Squibb | 55 | |
| Deborah JD | Gilead Sciences | 59 | |
| Arvind Sood | Amgen Inc | N/A | |
Management Performance
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 |
PT Kalbe Farma Leadership Team
Elected by the shareholders, the PT Kalbe's board of directors comprises two types of representatives: PT Kalbe inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PTKFF. The board's role is to monitor PT Kalbe's management team and ensure that shareholders' interests are well served. PT Kalbe's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PT Kalbe's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lanny Soputro, G HR | ||
| Kurniawan Suhartono, Head Unit | ||
| Bapak Vidjongtius, Corporate Secretary, Independent Director, Chairman of Good Corporate Governance Committee and Member of Bus. Risk Committee | ||
| Sie Djohan, Management Devel | ||
| Lukito Gozali, Head Relations |
PTKFF Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is PT Kalbe a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.12 % | |||
| Current Valuation | 6.11 B | |||
| Shares Outstanding | 46.26 B | |||
| Shares Owned By Insiders | 58.08 % | |||
| Shares Owned By Institutions | 15.23 % | |||
| Price To Book | 5.15 X | |||
| Price To Sales | 3.56 X | |||
| Revenue | 26.26 T |
Currently Active Assets on Macroaxis
Other Information on Investing in PTKFF Pink Sheet
PT Kalbe financial ratios help investors to determine whether PTKFF Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PTKFF with respect to the benefits of owning PT Kalbe security.